Nanoscope Therapeutics Initiates FDA Review for Gene-Agnostic Retinitis Pigmentosa Treatment

Hope on the Horizon: Nanoscope Therapeutics Advances Gene Therapy for Retinitis Pigmentosa

For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of potential new treatments offers a beacon of hope. Nanoscope Therapeutics has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy, MCO-010, aimed at treating severe vision loss due to retinitis pigmentosa (RP). This significant step brings the IRD community closer to a potential new therapeutic option, particularly for those with advanced disease regardless of their specific genetic mutation.

Key Milestones in the Journey to Approval

Nanoscope Therapeutics, a biotechnology company based in Fort Worth, is developing gene-agnostic therapies for retinal degenerative diseases. The company announced on July 14, 2025, that it began the rolling submission of its BLA for MCO-010 for retinitis pigmentosa. This is a notable event as it marks the first BLA submission for a gene-agnostic gene therapy for retinal disease.

MCO-010 is an optogenetic monotherapy designed to restore vision in patients with severe vision loss from RP. A key advantage of this therapy is its